Company Overview
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +1.77% |
| 6 Months: | +3.33% |
| 3 Months: | +44.62% |
| 1 Month: | +2.83% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)57.95 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AGMB AgomAb Therapeutics NV PHARMA | 14.91 | -9.50 | $734.29M | 0.00% | -43.87% | -39.22% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 11.81M | 16.53M |
| Operating Income | -11.81M | -16.53M |
| EBITDA | -11.80M | -17.62M |
| Interest Expense | -155.00K | -139.00K |
| Pretax Income | -11.73M | -17.40M |
| Tax Provision | 4.00K | 0 |
| Net Income | -11.73M | -17.40M |
| Diluted EPS | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 22.63M | 31.19M | 48.02M | 59.27M |
| Operating Income | -22.63M | -31.19M | -48.02M | -59.27M |
| EBITDA | -10.74M | -11.88M | -45.88M | -62.27M |
| Interest Expense | 45.00K | 31.00K | 67.00K | 60.00K |
| Pretax Income | -10.81M | -12.01M | -46.26M | -62.55M |
| Tax Provision | -2.66M | -619.00K | 4.00K | 0 |
| Net Income | -8.14M | -11.39M | -46.27M | -62.55M |
| Diluted EPS | -0.22 | -0.31 | -1.28 | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Eqt Fund Management S.a R.l. | 10.44% | 5.14M | $62.58M |
| 2 | Sanofi | 5.65% | 2.78M | $33.87M |
| 3 | Redmile Group, LLC | 5.55% | 2.73M | $33.27M |
| 4 | Cormorant Asset Management, LP | 5.01% | 2.47M | $30.00M |
| 5 | TCG Crossover Management, LLC | 4.17% | 2.05M | $24.99M |
| 6 | Federated Hermes, Inc. | 3.29% | 1.62M | $19.69M |
| 7 | Nantahala Capital Management, LLC | 3.18% | 1.57M | $19.08M |
| 8 | Casdin Capital, LLC | 3.15% | 1.55M | $18.86M |
| 9 | Andera Partners | 3.12% | 1.54M | $18.73M |
| 10 | FMR, LLC | 2.96% | 1.46M | $17.75M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AGMB
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Antwerp, Belgium, August 10, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has propos…
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD), including Novel Primary Endpoint of Endoscopic Passability -- …
Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. AgomAB Therapeutics NV (NASDAQ:AGMB) is one of the best up and coming stocks on our list. TheFly reported on June 22 that H.C. Wainwright initiated co…
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability -- -- Study initiation on track, with first participants expec…
Agomab to Participate in Upcoming Conferences
Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the followi…
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 -- -- Positive Interactions with U.S. Food and …
AGMB — Frequently Asked Questions
What is the current share price of AgomAb Therapeutics NV (AGMB)?
As of 2026-09-19 21:16 PDT, AgomAb Therapeutics NV (AGMB) trades at $14.91 on NasdaqGS. Its 52-week range is $9.61 to $17.82.
What is the market capitalisation of AGMB?
AgomAb Therapeutics NV (AGMB) has a market capitalisation of $734.29M on NasdaqGS.
What is the P/E ratio of AGMB?
AGMB trades at a trailing price-to-earnings (P/E) ratio of -9.50. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.68.
What is the return on equity (ROE) of AGMB?
AGMB has a return on equity (ROE) of -39.22%. Its return on capital employed (ROCE) is -43.87%.
Is AGMB a good stock to buy?
This page provides a data-driven analysis of AgomAb Therapeutics NV (AGMB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.